In Africa, the number of people suffering from HIV/AIDS has reached upwards of 20,000,000 in 2002 and 42,000,000 worldwide. These figures are expected to increase to nearly 100,000,000 by 2010. With HIV/AIDS reaching pandemic magnitudes, the Company is focusing its product launch initiatives on HIV/AIDS in Africa and then to other countries, Europe and the United States.

Our approach to combat disease is unique from the common practice of using antimicrobial agents that can be toxic; rather, it utilizes the basic science within the white blood cells, called ‘the respiratory burst.’ The respiratory burst is the process by which the body’s immune system produces bio-oxidants to destroy abnormal cells and invading microorganisms. Trioxolane emulates this process by producing oxidative metabolites that are anti-microbial, immuno-stimulatory and non-toxic. This approach reinforces the natural immune system in combating harmful agents and regulates the production of serotonin, prostaglandin and inflammatory interleukins.